Market Spotlight: Uterine Fibroids
|出版日期||內容資訊||英文 44 Pages
|關注市場分析:子宮肌瘤 Market Spotlight: Uterine Fibroids|
|出版日期: 2019年12月02日||內容資訊: 英文 44 Pages||
This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2017, there were approximately 92.2 million prevalent cases of uterine fibroids worldwide in females aged 15 years and over, and forecasts that number to increase to 102.7 million prevalent cases by
2026. Lupron and relugolix, which target gonadotropin-releasing hormone receptor, and ulipristal acetate, which targets progesterone receptor, are the only approved drugs for uterine fibroids. These drugs are administered via the oral and subcutaneous routes.
Half of the industry-sponsored drugs in active clinical development for uterine fibroids are in Phase III, with one drug in the NDA/BLA phase.
Therapies in development for uterine fibroids focus on targets such as progesterone receptor, gonadotropin-releasing hormone receptor, and collagen. The majority of pipeline drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
High-impact upcoming events for drugs in the uterine fibroids space comprise topline Phase III trial results and an expected meeting with the FDA for linzagolix, and an estimated PDUFA date for Orilissa.
The overall likelihood of approval of a Phase I gynecology asset is 13.3%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 10.6 years from Phase I to approval, compared to 12.4 years in the overall obstetrics/gynecology space.
There have been 13 licensing and asset acquisition deals involving uterine fibroids drugs during 2014-19. The values have not been disclosed for any of these deals.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for uterine fibroids have been in the early and mid-phases of development, with 60% of trials in Phase I-II, and 40% in Phase III-IV.
The US has a substantial lead in the number of uterine fibroids clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the uterine fibroids space is dominated by completed trials. Repros Therapeutics has the highest number of completed clinical trials for uterine fibroids, with 17 trials.
Repros Therapeutics leads industry sponsors with the highest number of clinical trials for uterine fibroids, followed by Takeda
9 Medical agents
19 Relugolix for Uterine Fibroids (July 23, 2019)
20 Multiple Drugs for Uterine Fibroids (June 25, 2019)
21 Relugolix for Uterine Fibroids (May 14, 2019)
23 Vilaprisan for Uterine Fibroids (December 05, 2018)
24 Ekobi 500 Embolization Microspheres for Uterine Fibroids (November 20, 2018)
26 Orilissa for Uterine Fibroids (August 22, 2018)
28 Ulipristal Acetate for Uterine Fibroids (August 21, 2018)
29 Ulipristal Acetate for Uterine Fibroids (May 18, 2018)
32 AbbVie Revs Up The Race To Market In Uterine Fibroids
32 Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie
34 Deals Shaping The Medical Industry, August 2019
34 QXMedical Gets Exclusive Rights To University of Minnesota Bioresorbable Technology
39 Sponsors by status
40 Sponsors by phase
41 Recent events
42 Prescription information